Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals

Journal of Infectious Diseases

Volumn 178, Issue 4, 1998, Pages 1205-1208

  Opal, Steven M ^a   Jhung, Jhung W ^b   Keith Jr , James C ^b   Palardy, John E ^b   Parejo, Nicolas A ^b   Young, Lynette D ^b   Bhattacharjee, Apurba ^b  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; RECOMBINANT INTERLEUKIN 11; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENDOTOXIN DETECTION; HISTOPATHOLOGY; IMMUNE DEFICIENCY; INFLAMMATION; INTESTINE NECROSIS; INTRAVENOUS DRUG ADMINISTRATION; LUNG EDEMA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031684607     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515686     Document Type: Article

References (15)

1. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992; 327:28-35.
2. Opal SM, Cross AS, Jhung JW, et al. Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J Infect Dis 1996;173:1415-21.
3. Paul S, Bennett F, Calvetti J, et al. Molecular cloning of a cDNA encoding interleukin-11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990;84:7512-6.
4. Opal SM, Keith J Jr. Interleukin-11 as a potential therapeutic modality in sepsis. In: Vincent JL, ed. Yearbook of intensive care and emergency medicine. Berlin: Springer-Verlag, 1996:111-8.
5. Du XX, Doerschuk CM, Orazi A, Williams DA. A bone-marrow-stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1994;83:33-7.
6. Potten CS. Interleukin-11 protects the clonogenic stem cells in murine small intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer 1995;62:356-61.
7. Keith JC Jr, Albert L, Sonis ST, Pfeiffer CJ, Schaub RG. IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 1994; 12:79-90.
8. Barton BE, Shortall J, Jackson JV. Interleukins-6 and -11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun 1996;64:714-8.
9. Trepicchio WL, Wang L, Bozza M, Dorner AJ. IL-11 regulates macro-phage effector function through the inhibition of nuclear factor-κB. J Immunol 1997;159:5661-70.
10. Misra BR, Ferranti TJ, Donnelly LH, Erickson JE, Keith JC Jr, Schaub RG. Recombinant interleukin-11 prevents hypotension in lipopolysaccharide-treated anaesthetized rabbits. J Endotoxin Res 1996;3:297-305.
11. Fox AD, Kripke SA, DePaula J, Berman JM, Settle RG, Rombeau JL. Effect of a glutamine-supplemented enterai diet on methotrexate-induced enterocolitis. J Parenter Enterai Nutr 1988;12:325-31.
12. Yin T, Taga T, Tsang MLS, Yasukawa K, Kishimoto T, Yang YC. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J Immunol 1993;155:2555-61.
13. Sonis S, Clark J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology 1991;5:11-8.
14. Tancreda CH, Andrement AO. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 1985;152:99-103.
15. Tepler I, Elias L, Smith JW, et al. A randomized, placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87:3607-14.